Status:
COMPLETED
Factors and Prognostic Significance of Impaired Exercise Tolerance in Women Over 40 With Arterial Hypertension
Lead Sponsor:
Polish Mother Memorial Hospital Research Institute
Conditions:
Arterial Hypertension
Heart Failure
Eligibility:
FEMALE
40-99 years
Phase:
NA
Brief Summary
The subject of the study is evaluation of factors affecting to exercise intolerance in spiroergometry in women over 40 years of age with hypertension and association and relationship between the param...
Detailed Description
The 185 women over 40 years of age hospitalized for arterial hypertension in the Department of Cardiology will be included in the study, including: the study group who demonstrated maximal oxygen cons...
Eligibility Criteria
Inclusion
- Age equal to or older than 40 years
- Arterial hypertension (HA) diagnosed according to the 2018 European Society of Cardiology (ESC) guidelines of HA \[1\]
- Current HA hospitalization
Exclusion
- Severe hypertension
- Diagnosis of heart failure or typical symptomatic heart failure
- Left ventricular ejection fraction (LVEF) \<50%
- Documented: hyperandrogenism, hyperestrogenism, insulin resistance, premature ovarian failure, polycystic ovary syndrome
- Past myocardial infarction
- Diagnosis of cardiomyopathy (hypertrophic, dilated, restrictive, peripartum, arrhythmogenic)
- Lysosomal storage disorders
- Stroke, transient ischemic attack, Intracerebral hemorrhage in medical history
- Severe hyper- and hypothyroidism
- Pregnancy and lactation
- Chronic kidney disease (IV, V stadium according to National Kidney Foundation) and dialysis treatment
- Documented neoplastic process
- The patient's inability to cooperate and/or provide informed consent to participate in a research
- Alcohol and drug abuse
- Active autoimmune disease
- Treatment using immunosuppressants, cytostatic drugs, glucocorticosteroids, or antiretroviral drugs
- A history of bone marrow transplant or other organ transplant, treatment with blood products within the last 6 months
- Active systemic infection
- Hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) carrier or positive for hepatitis B surface antigen (HBSAg) or antibodies to HCV
- Surgery or serious injury within the last month
- Patients who did not express their informed consent to participate in the study
Key Trial Info
Start Date :
February 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT04802369
Start Date
February 1 2019
End Date
February 28 2021
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Failure Unit; Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute
Lodz, Poland, 93-338